A study on the efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infections.
Not Applicable
- Conditions
- Influenza virus infection
- Registration Number
- JPRN-UMIN000005015
- Lead Sponsor
- Department of Clinical Infectious Diseases, Aichi Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with convulsions or other neurological symptoms ( consciousness disorder, abnormal behavior/speech ) within the past 2 years. 2) History of hypersensitivity, allergy or serious adverse drug event caused by oseltamivir phosphate ( Tamiflu ), zanamivir hydrate ( Relenza ) or peramivir hydrate ( Rapiacta ). 3) Women who are pregnant or suspected to be pregnant and women who are breast-feeding. 4) Any other patients whose condition is inappropriate for the evaluation of this clinical study as judged by the investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The improvement in clinical status ( improvement ratio )
- Secondary Outcome Measures
Name Time Method The time to alleviation of influenza symptoms. Incidence of influenza-related complications.